1The Proteome Landscape of Human Placentas for2Monochorionic Twins with Selective Intrauterine Growth3Restriction

- 4
- 5 Xin-Lu Meng^{1,#}, Peng-Bo Yuan^{1,#}, Xue-Ju Wang¹, Jing Hang^{2,3,4,5}, Xiao-Ming Shi¹,
- 6 Yang-Yu Zhao^{1,*}, Yuan Wei^{1,*}
- 7
- ⁸ ¹ Department of Obstetrics and Gynecology, Peking University Third Hospital,
- 9 Beijing 100191, China
- ¹⁰ ² Center for Reproductive Medicine, Department of Obstetrics and Gynecology,
- 11 Peking University Third Hospital, Beijing 100191, China
- ³ Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing 100191,
- 13 *China*
- ⁴ Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproduction,
- 15 Beijing 100191, China
- ⁵ National Clinical Research Center for Obstetrics and Gynecology, Beijing 100191,
- 17 *China*
- 18
- 19 [#] Equal contribution.
- 20 ^{*} Corresponding authors.
- 21 E-mail: <u>weiyuanbysy@163.com</u> (Wei Y), <u>zhaoyangyu@bjmu.edu.cn</u> (Zhao YY).
- 22

23 Abstract

24 In perinatal medicine, intrauterine growth restriction (IUGR) is one of the greatest 25 challenges. The etiology of IUGR is multifactorial, but most cases are thought to arise 26 from placental insufficiency. However, identifying the placental cause of IUGR can 27 be difficult due to numerous confounding factors. Selective IUGR (sIUGR) would be 28 a good model to investigate how impaired placentation affects fetal development, as 29 the growth discordance between monochorionic twins cannot be explained by 30 confounding genetic or maternal factors. Herein we constructed and analyzed the 31 placental proteomic profiles of IUGR twins and the normal cotwins. Specifically, we 32 identified a total of 5481 proteins and 233 differentially expressed proteins (DEPs), 33 including 57 upregulated and 176 downregulated DEPs in IUGR twins. Bioinformatic 34 analysis indicates that these DEPs are mainly associated with cardiovascular system 35 development and function, organismal survival, and organismal development. Notably, 36 34 DEPs are significantly enriched in angiogenesis, and diminished placental 37 angiogenesis in IUGR twins has been further elaborately confirmed. Moreover, we 38 found decreased expression of *metadherin (MTDH)* in placentas for IUGR twins and 39 demonstrated that MTDH contributes to placental angiogenesis and fetal growth in 40 vitro. Collectively, our findings reveal the comprehensive proteomic signature of 41 placentas for sIUGR twins, and the DEPs identified may provide in-depth insights 42 into pathogenesis of placental dysfunction and subsequent impaired fetal growth.

43

44 KEYWORDS: Selective intrauterine growth restriction; Placenta; Proteome; 45 Angiogenesis; *Metadherin*

46

47 Introduction

48 Intrauterine growth restriction (IUGR), which refers to the inability of the fetus to 49 reach its full growth potential, is among the most common pregnancy complications 50 and affects 7% of pregnancies worldwide [1]. Besides contributing to significant 51 perinatal and pediatric morbidity and mortality, it can also raise the risk of developing 52 metabolic, cardiovascular, and respiratory disorders later in life [2,3]. Despite the 53 involvement of multiple factors, placental insufficiency has been reported as a major 54 cause of IUGR [4,5]. Placental insufficiency refers to a process of progressive 55 deterioration of placental function. It reduces transplacental oxygen and nutrients 56 transfer to the growing fetus, and ultimately limits placental performance during 57 pregnancy [6,7]. However, identifying the molecular mechanisms underlying 58 pathogenesis of placental insufficiency is challenging due to the interference of 59 numerous maternal and genetic confounding factors.

60 Selective IUGR (sIUGR) is a unique complication of monochorionic (MC) twins 61 in which one twin is an IUGR fetus and the cotwin grows normally. An estimated 10%–15% of MC pregnancies suffer from it [8]. Several studies have extensively 62 63 investigated the development of sIUGR at the gross histopathological level and have 64 shown that sIUGR is associated with a remarkable discordance of placental sharing 65 wherein the IUGR twin is supported by a smaller portion of the placenta. Also, a 66 higher incidence of abnormal cord insertion occurs in the smaller fetuses [9,10]. 67 Additionally, the terminal branch levels of the placental artery and vein were 68 significantly lower in the IUGR twins [11]. Together, these morphological alterations 69 suggest placental insufficiency and impaired blood perfusion to the fetus in sIUGR. 70 The two fetuses harbor an identical genotype and share the same maternal 71 environment. Thus, sIUGR twins would provide an ideal model to investigate the 72 underlying mechanisms of placental insufficiency by using the healthy cotwin as an 73 internal control to eliminate confounding maternal and genetic factors and to ensure 74the same gestational age. Recent studies have found that dysregulation of several 75 angiogenesis-related genes, such as endoglin and fms-like tyrosine kinase 1 (FLT1),

76 may contribute to the development of sIUGR [12–14]. The hypoxia inducible 77 factor-1a (HIF1A) mRNA levels, as well as 8-hydroxydeoxyguanosine (8-OHdG) and 78 malondialdehyde (MDA), both biomarkers of oxidative stress, have been 79 demonstrated to be significantly upregulated in IUGR twin placentas, suggesting that 80 oxidative stress might participate in the pathogenesis of sIUGR [15]. In other studies, abnormal placental epigenetic modification, such as altered imprinted genes and DNA 81 82 methylation, has been found to cause sIUGR [16,17]. However, a systematic placental 83 proteomic profile linked with the functional analysis of clinical sIUGR is still absent.

In this study, we systematically investigated the placental proteome differences 84 between IUGR twins and the normal cotwins utilizing tandem mass tag (TMT)-based 85 86 technology. In total, we identified 5481 proteins and 233 differentially expressed 87 proteins (DEPs), of which 57 were upregulated and 176 were downregulated. 88 Bioinformatic analysis by ingenuity pathway analysis (IPA) revealed that these DEPs 89 were most significantly enriched in cardiovascular system development and function, 90 as well as organismal survival and organismal development. Notably, 34 DEPs were 91 associated with the biological process of angiogenesis, and we found that 92 angiogenesis was significantly impaired in IUGR twin placentas. The differential 93 expression of ephrin B2 (EFNB2), vimentin (VIM) and methionyl aminopeptidase 2 94 (METAP2), which are essential in placental angiogenesis, was validated by PCR and 95 immunohistochemistry analysis. In addition, we found that metadherin (MTDH) was 96 significantly downregulated in IUGR twin placentas. Knockdown of MTDH in human 97 umbilical vein endothelial cells (HUVECs) obviously inhibited the proliferation, 98 migration, tube formation, and spheroid sprouting by affecting numerous genes and 99 biological processes. In brief, our study is the first comprehensive analysis of the 100 placental proteomic profile in sIUGR twins and may offer deeper insights into the 101 molecular mechanisms of IUGR.

102

103 **Results**

104 Clinical characteristics

105 To identify novel candidate molecules for sIUGR, we harvested 12 placental samples 106 from six sIUGR twin pairs and performed TMT-based comparative proteomic 107 analysis. sIUGR twins, which share the maternal environment and harbor an identical 108 genotype, provide an ideal model for investigating the association between placental 109development and fetal growth. The demographics and clinical characteristics of the 110 twin pregnancies in this study are presented in Table S1 and Figure S1A–D. All twins 111 were delivered alive by cesarean section at a mean gestational age of 32.3 ± 1.2 weeks. 112 The birth weight of the IUGR twins was, on average, 628 grams lower than that of their healthy cotwins (P = 0.0004), with relative birth weight discordance ranging 113 114 from 25.2% to 48.0%. None of the study population had twin-to-twin transfusion 115 syndrome, fetal malformations, and maternal complications such as preeclampsia or diabetes mellitus. In addition, IUGR twin placentas exhibited more pathological 116 117 abnormalities, including distal villous hypoplasia, intervillous fibrin deposition, 118 increased syncytial knots, and abnormal cord insertion. (Figure S1E-I).

119 Comparative proteomic analysis identifies 233 DEPs in IUGR twin placentas

120 To comprehensively profile the global placental proteomic changes between IUGR 121 twins and normal cotwins, we applied a high-accuracy quantitative proteomic 122 approach to analyze protein expression (Figure 1A). A total of 12 samples from 6 123 pairs of sIUGR twins were processed in the same experimental period. After protein extraction, reduction, alkylation, and digestion, each 3 pairs of sIUGR twins were 124 125labeled with one set of six-plex TMT reagent (group 1: TMT 126, 127, and 128 for 126 normal cotwin 1, 2, and 3; TMT 129, 130, and 131 for IUGR twin 1, 2, and 3 127 respectively; group 2: TMT 126, 127, and 128 for normal cotwin 4, 5, and 6; TMT 128 129, 130, and 131 for IUGR twin 4, 5, and 6 respectively). Six isobaric labeled 129 samples within the same set were mixed together and then separated into 10 fractions 130 by high pH reversed-phase liquid chromatography (RPLC). All 20 fractions from two 131 TMT sets were subjected sequentially to liquid chromatography tandem mass 132 spectrometry (LC-MS/MS). MS data were then collected and analyzed for protein 133 identification and quantification. Details on MS data analysis were presented in the Methods section. Specifically, we identified a total of 5481 nonredundant proteins in 134

135 sIUGR twin placentas (Table S2). A histogram plot revealed the fold change (FC) 136 distribution of all identified proteins (Figure 1B). The distribution of statistical 137 significance ($-\log_{10}$ transformed P value) and degree of change (\log_2 transformed FC) 138 for all identified proteins were presented in the volcano plot (Figure 1C). Using a combination of P < 0.05 and |FC| > 1.3, 233 proteins displayed significant differential 139expression in IUGR twin placentas compared to the normal cotwin placentas. Of these, 140 141 57 DEPs were upregulated and 176 DEPs were downregulated (Table S3). 142 Unsupervised hierarchical clustering of the DEPs revealed good separation between 143 the two groups (Figure 1D).

To deepen the biological insights into these DEPs, we utilized IPA software for 144 145 bioinformatics analysis. The core biofunction analysis of these DEPs was divided into 146 three categories. In "physiological system development and function" category, the 147 most significantly enriched item was "cardiovascular system development and 148 function", which involved 52 DEPs. The other two main enriched subcategories were "organismal survival" (number of DEPs in this function [n] = 66) and "organismal 149 150development" (n = 71) (Figure 1E; Table S4). In addition, in "molecular and cellular 151 function" category, the top three enriched functions included "cell death and survival", 152"lipid metabolism", and "molecular transport" (Figure S2A; Table S4). For "diseases 153and disorders", the DEPs were significantly related to "endocrine system disorders", 154 "gastrointestinal disease", and "metabolic disease" (Figure S2B; Table S4). 155 Additionally, IPA canonical pathway analysis identified oxidative phosphorylation, 156mitochondrial dysfunction, and the Sirtuin signaling pathway as the top three 157 pathways that might be potentially affected in IUGR twin placentas (Figure S2C).

158 Angiogenesis is significantly impaired in IUGR twin placentas

Among the 52 DEPs involved in "cardiovascular system development and function", 34 DEPs were enriched in the biological process of angiogenesis encompassed in this biofunction, and the state of angiogenesis was predicted to be suppressed by IPA (**Figure 2**A). Placental angiogenesis is crucial to villous development and placental function. Any impairment in placental angiogenesis can lead to poor placentation, decreased blood flow to the fetus, and various pregnancy complications [18]. To

165 confirm whether angiogenesis was altered in IUGR twin placentas, we assessed the 166 microvessel density (MVD) and vascular area density per sample following 167 immunostaining of CD34 as an endothelial cell marker. A significant decrease in 168 MVD was present in IUGR twin placentas, while the vascular area density was also 169 significantly lower in IUGR twin placentas than in the normal cotwins (Figure 2B–D). 170 Taken together, these data suggested that impaired placental angiogenesis in IUGR 171 twins might be responsible for the development of sIUGR. To further validate the 172proteomic results, we selected 3 markers (EFNB2, VIM, and METAP2) for 173 immunohistochemistry analysis. The 3 markers were reported to play essential roles 174 in placental angiogenesis and fetal development [19–21]. As shown in Figure 2E–H, 175 the intensity of VIM, EFNB2, and METAP2 immunoreactivity was significantly 176 lower in IUGR twin placentas than in normal cotwins, which was in line with TMT 177 proteomic results. Additionally, we performed qRT-PCR to explore their expression 178 changes at mRNA level. Similar to the proteomic data, VIM, EFNB2, and METAP2 179 mRNA expression levels were significantly downregulated in IUGR twin placentas 180 (Figure 2I–K).

181 *MTDH* silencing inhibits HUVEC proliferation and migration

182 Among the 34 DEPs related to angiogenesis, we also observed a significant decrease 183 in *MTDH* expression in IUGR twin placentas (**Figure 3**A–C). There is evidence that 184 MTDH participates in tumor angiogenesis [22,23], while its role in placental 185 angiogenesis remains unclear. During placental angiogenesis, endothelial cells 186 undergo proliferative, migratory, and morphological events to form a vessel network. 187 To investigate the causality between endothelial MTDH deficiency and sIUGR 188 development, the role of *MTDH* in the proliferation and migration of HUVECs was 189 explored. HUVECs were transfected with negative control siRNA (si-NC) and siRNA 190against MTDH (si-MTDH). Transfection with si-MTDH markedly decreased MTDH 191 mRNA and protein levels (Figure 3D–F). The proliferation and migration abilities of 192 HUVECs were examined using an electrical impedance-based tool, the 193 xCELLigence® real-time cell analysis (RTCA) system, which enables continuous 194 monitoring of cell behaviors and allows for real-time assessment of multiple cell

195functions. For the proliferation assay, cells treated with si-NC or si-MTDH were 196seeded in the wells of an E-plate. Cells were cultured for 60 h, and the si-MTDH 197 group exhibited a significant reduction in proliferation ability (Figure 3G). Cell 198 migration was assessed using a CIM-16 plate with upper and lower chambers in each 199well. The results revealed that MTDH interference obviously decreased HUVEC 200 migration ability compared with that of control cells (Figure 3H). To further confirm 201 the effect of *MTDH* deficiency on HUVEC migration in the horizontal direction, we 202 performed a wound healing assay. As expected, the wound in the 203 si-MTDH-transfected cell culture healed more slowly than that of the control group 204 (Figure 3I, J). In summary, these findings demonstrated that MTDH is vital to 205 HUVECs proliferation and migration.

Knockdown of *MTDH* inhibits tube formation and spheroid sprouting in HUVECs

208 To further determine *MTDH*'s effect on placental angiogenesis, the 2-dimensional (2D) 209 tube formation assay and 3-dimensional (3D) spheroid sprouting assay were 210 conducted using HUVECs. As shown in Figure 4A, si-NC-transfected HUVECs 211 could form capillary-like structures in a few hours on Matrigel, while the tube 212 formation capacity was perturbed in the si-*MTDH* group. *MTDH* deficiency distinctly 213 impaired the number and area of tubes, the total tube length, as well as the number of 214 branching points (Figure 4B–E). Similarly, when embedded in 3D collagen I gels, 215 spheroids composed of si-NC-transfected HUVECs retained the ability to produce 216 capillary-like outgrowths, while only a few sprouts were formed in MTDH-depleted 217 HUVEC spheroids (Figure 4F). Compared to the control cells, the si-MTDH HUVECs 218 exhibited a significant reduction in cumulative sprout length (Figure 4G). Accordingly, 219 these data suggest that downregulation of *MTDH* inhibits placental angiogenesis.

220 *MTDH* is required in placental development and fetal growth

To verify whether *MTDH* is required in placental and fetal development, we knocked down *MTDH* in HUVECs and performed RNA-seq analysis. Both the control and si-*MTDH* groups had three biological replicates each. The correlation analysis based on the overall RNA-seq data for each sample pair showed that the correlation

225 coefficient between intra-group samples was higher than that between inter-group 226 samples, indicating that samples within groups had strong resemblance in terms of 227 transcription pattern and the biological experimental operations were reliable and 228 reproducible, while the gene expression changed following MTDH interference. 229 (Figure 5A). The top 50 protein-coding genes with significantly differential 230 expression (adjusted P < 0.05) were selected as candidates for further analysis (Table 231 S5). Among the 50 genes, 29 were upregulated and 21 were downregulated in the 232si-MTDH group. The expression profiles of the 50 genes are presented in a heatmap 233 (Figure 5B). Further functional enrichment analysis revealed that 50 candidate genes 234 were associated with various biological processes, such as defense responses, 235 apoptotic processes, actin filament organization, negative regulation of cell 236proliferation, and angiogenesis (Figure 5C). The interaction network of the 50 237 candidates is presented in Figure 5D.

238 Among the 50 candidates, we found quite a few genes previously reported to be 239implicated in placental dysfunction and fetal growth restriction, including PSG3 240 (upregulation of *PSG3* in both maternal blood and IUGR placenta) [24,25], *CSF2* 241 (Csf2-deficient mice exhibit placental insufficiency and fetal growth retardation) 242 [26,27], THSD7A (higher expression of THSD7A is associated with low birth weight) 243 [28], CYP1B1 (lower methylation levels of CYP1B1 are found in preterm delivery 244 with reduced fetal growth) [29], and PLCL1 (double-knockout mice for Plcl1 and 245 *Plcl2* exhibit reduced litter events and litter size) [30]. These results further provide 246 support for the validity of our results. Interestingly, we also found several unreported 247 genes that may affect placental development and fetal growth, such as IFITM2, 248 TMSB15A, and WAS. These findings may help further the discovery of potential 249 biomarkers and therapeutic targets.

250

251 **Discussion**

Despite advances in perinatal care, IUGR remains a challenging problem faced by obstetricians worldwide. Placental insufficiency and subsequent undernutrition and

254hypoxia are considered to be the ultimate pathomechanisms that disturb fetal growth 255[31]. However, the molecular regulatory mechanisms of IUGR have not been fully 256elucidated due to genetic and maternal heterogeneity. In monochorionic twin 257pregnancy, the IUGR twin and the normal cotwin have an identical genotype and 258develop in the same uterus, making it an excellent model to investigate placental 259disorders [32]. Proteins, which act as the ultimate executors of gene function, are vital 260 players within organisms in terms of functionality and structure [33]. Thus, 261 investigating the molecular basis for IUGR at the protein level is of paramount 262 importance to shed light on its clinical diagnosis and treatment. Based on the above 263 information, we sought to construct a comprehensive profile of the placental DEPs by 264 taking advantage of sIUGR twins. In this work, we performed TMT-based 265 comparative proteomic studies using placental samples of six sIUGR twin pairs from 266 the clinic. A total of 5481 unique proteins with high confidence were detected in 267 human placental tissues. Therein, 233 proteins were identified as DEPs between 268 IUGR twin and normal cotwin placentas, with 57 upregulated and 176 downregulated. 269In the current work, numerous proteins relevant to embryonic development were 270found to be dysregulated in IUGR twin placentas. As the interface of interaction and 271 communication between mother and fetus, the placenta is essential to embryo 272 development and, in particular, to fetal growth [34]. The aberrant expression of these 273 proteins in IUGR twin placentas implies that they may play key roles in impairing 274 fetal growth potential. In addition, a set of proteins that can modulate lipid 275metabolism were detected in our study. Over the past few decades, lipid metabolism 276 during pregnancy has been highlighted as essential not only for optimal placental 277 development and function but also for proper intrauterine growth of the fetus [35]. 278 Disrupted lipid metabolism may contribute to placental insufficiency and suboptimal 279fetal growth, which is consistent with previous discoveries in singleton IUGR cases 280 [36,37]. In addition, proteins that are key players in molecular transport appeared 281 prominently among the top functional terms. In fact, the formation of an efficient 282 transport interface is the essence of the placenta, which allows the growing fetus to 283 fulfill its developmental demands from maternal circulation [34]. Alterations in

nutrient transporter expression have also been evidenced in IUGR placentas [38,39].

285 Notably, we found that 34 DEPs were implicated in angiogenesis. Adequate 286 angiogenesis ensures that placentas develop as highly vascularized organs, thereby 287 supporting the blood flow required for fetal growth [40]. Aberrant placental 288 vasculature has been identified in nearly all human pregnancy complications, further 289 confirming the importance of placental angiogenesis for normal pregnancy [41]. A 290previous study discovered significantly decreased villus vascular density in placentas 291of singleton IUGR [42]. Our results also confirmed that placental MVD and vascular 292 area density were significantly lower in smaller fetuses. These results together suggest 293 that impairment of placental angiogenesis may play key roles in the incidence and 294 development of IUGR. MTDH, also known as AEG-1, is implicated as an oncogene 295[43,44]. According to our findings, *MTDH* was significantly downregulated in IUGR 296 twin placentas and located in intravillous capillary endothelial cells. In addition, we 297verified that the function of *MTDH* is critical in placental angiogenesis, indicating that 298 decreased expression of MTDH may contribute to the pathogenesis of placental 299dysfunction and fetal growth retardation. While our understanding of the molecular 300 mechanisms of IUGR has advanced significantly over the past few decades, there are 301 currently no reliable diagnostic biomarkers or targeted therapies available for this 302 disease in clinical practice [45,46]. Translational application of the candidate targets 303 identified in singleton IUGR pregnancies is very limited, probably mainly due to the 304 heterogeneity of the samples in these studies. Thus, MTDH identified in our 305 investigation using sIUGR twins may serve as a potential biomarker for early 306 prediction and accurate diagnosis of IUGR, as well as a novel target for future 307 treatment. In summary, our findings comprehensively described the proteomic 308 landscape of sIUGR twin placentas, which may provide reliable resources for 309 mechanistic studies of the core regulators involved in placental dysfunction and fetal 310 growth restriction.

311

312 Materials and methods

313 Patients and clinical specimen collection

314 Placental samples from 6 sIUGR twins were collected at Peking University Third 315 Hospital. Ultrasonography at 11-14 weeks was conducted to determine the 316 chorionicity, and postnatal placental examination was used to confirm it. sIUGR 317 refers to a monochorionic twin in which the estimated fetal weight (EFW) of one 318 fetus is lower than 10th percentile while the cotwin's is normal and the intertwin EFW 319 discordance is more than 25%. EFW was calculated based on Hadlock formula [47]. 320 EFW discordance was calculated with this formula: (normal cotwin EFW-IUGR twin 321 EFW)/normal cotwin EFW. All participants underwent cesarean delivery, and the 322samples were collected within 30 min. Samples were obtained from the maternal side 323 of the placental lobules within 2 cm of each umbilical cord insertion site, aiming to 324 reduce possible bias caused by the regional variations in placental gene expression 325 associated with the sampling sites [48,49]. The placental biopsies were excised in 326 areas free of macroscopic lesions of calcification or infarction after removing the 327 maternal deciduas and fetal membranes. The biopsy was washed in PBS for blood 328 removal. A portion of the sample was stored at -80° C after freezing in liquid nitrogen. 329 The rest was fixed in 10% formalin solution followed by embedding in paraffin.

330 **Protein extraction, digestion, and TMT labeling**

331 Placental tissues were lysed using 7 M urea with 1% (w/v) dithiothreitol (DTT), 2 M 332 thiourea, and 1% (v/v) protease inhibitor cocktail. Equal amounts of protein (100 333 µg/sample) were used for subsequent processing. 1 M DTT was used for peptide 334 reduction at 56°C for 30 min and 1 M iodoacetamide for alkylation at room 335 temperature for 30 min in darkness. Samples were diluted with 25 mM (pH 8.2) 336 Tris-HCl and 0.1 M CaCl2 until the final concentration of urea was 1 mM. Trypsin 337 (Catalog No. V5111, Promega, Madison, WI) was used to digest proteins for 12 h. 338 The resulting peptides were desalted on Sep-Pak C18 columns (Waters, Altrincham 339 Road, Wilmslow, UK), and then labeled with two sets of six-plex TMT reagents 340 (Catalog No. 90062, Thermo Fisher Scientific, Waltham, MA). Each 6 isobaric 341 labeled samples within the same set were combined and vacuum dried for further 342 analysis.

343 LC-MS/MS

344 The peptide mixture was separated into 10 fractions by high pH RPLC using BEH 345 C18 columns (1.7 μ m, 1.0 mm \times 150 mm) attached to the H-Class System (Waters). 346 The second-dimensional liquid chromatography separation of the peptides was conducted on the EkspertTM nano LC 415 instrument (AB Sciex, Toronto, Canada). 347 The peptides were eluted using 2% acetonitrile with 0.1% formic acid as buffer A and 348 349 98% acetonitrile with 0.1% formic acid as buffer B with a gradient of 100 min. The 350 eluted peptides were subsequently analyzed using TripleTOF 5600+ mass 351 spectrometer (AB Sciex). Data were obtained in positive ion mode. For TOF-MS scan, 352 the mass range was set as $350-1500 \square m/z$. The MS/MS scan was carried out with a 353 mass range of $100-1500 \square m/z$.

354 Data analysis

355 The raw data were analyzed by using the MaxQuant software (Version 1.5.2.8) [50] 356 and the human UniProt reference protein sequences [51] to generate initial 357 spectra-peptide matches and quantification values. The search was performed with the 358 following parameters: enzyme, trypsin/p; max missed cleavages, 2; 0.1 Da for first 359 search mass tolerance; 0.01 Da for main search mass tolerance; variable modifications, 360 acetylation (N-term) and oxidation (M); fixed modification, carbamidomethyl (C). 361 Protein identification requires at least one unique peptide. False discovery rate (FDR) 362 was 0.05 for both peptide and protein identification. Then, the MaxQuant results were 363 further processed by the MaxReport software [52] to correct and optimize the 364 quantitative results. In brief, the reporting intensity of each isobaric label was 365 corrected by an impurity correction matrix. Additionally, each label (sample) was 366 normalized by the total intensity. Then, the relative protein expressions were 367 calculated by the Libra algorithm [53]. Finally, DEPs were determined by P < 0.05368 and |FC| > 1.3. The MaxReport quantification workflow was also successfully tested 369 by using a benchmark dataset (PXD000001) to quantify the spiked reference proteins. 370 Additionally, all of the samples were harvested and processed in the same 371 experimental period. Due to the limited number of TMT labels, these samples were 372 labeled separately and loaded into the mass spectrometer in a sequential process.

373 Comparison of the average intensities and unique peptides between the two six-plex 374 TMT experiments indicated that there was a minor batch effect between the two 375 groups, as the Pearson correlation coefficient values for intensities and peptides were 376 0.96 and 0.98, respectively. Considering only two sequential batches in this study, we 377 did not perform such correction. The global protein expression patterns of sIUGR 378 twin placentas were illustrated using histograms and volcano plots in the R package 379 (version 3.5.2). Hierarchical cluster analysis of the DEPs was performed with MeV 380 software (version 4.9.0). We used IPA software (QIAGEN, Redwood City, CA) to 381 identify the biofunctions that were significantly associated with the DEPs. 382 Specifically, the list of DEPs, containing gene symbols, fold changes and P values, 383 was uploaded into IPA software for core analysis. The core analysis included 384 enrichment of diseases and functions, canonical pathways, and networks. The core 385 analysis was conducted with the setting of direct and indirect relationships between 386 focused genes based on the human section of "Ingenuity Knowledge Base", which 387 was a manually curated database of biological interactions and functional annotations.

388 Immunohistochemistry

389 After deparaffinization, antigen retrieval and endogenous peroxide blocking, the 390 sections (5 μ m in thickness) were incubated with primary anti-CD34 antibody 391 (Catalog No. ZM-0046, ZSGB-BIO, Beijing, China), anti-EFNB2 antibody (1:50; 392 Catalog No. HPA008999, Atlas Antibodies, Bromma, Sweden), anti-METAP2 393 antibody (1:3000; Catalog No. HPA019095, Atlas Antibodies), anti-VIM antibody 394 (Catalog No. ZM-0260, ZSGB-BIO) and anti-MTDH antibody (1:150; Catalog No. 395 ab124789, Abcam, Cambridge, UK). After incubating with secondary antibodies, the 396 sections were stained with diaminobenzidine solution (Catalog No. ZLI-9018, 397 ZSGB-BIO). The expression level of the target genes was assessed with Image-Pro 398 Plus (Media Cybernetics, Rockville, MD).

399 MVD and vascular area density

Using CD34 as an endothelial cell marker, the MVD was used to evaluate placental
angiogenesis by measuring the immunostaining of CD34 in placental sections. Briefly,
the number of CD34-positive vessels was counted under a magnification of 400× in 5

403 nonconsecutive fields by two observers who were blinded to the control and case 404 groups. The mean value of the 5 fields was expressed as the MVD. The vascular area 405 density was evaluated as follows: 5 images per slide with a magnification of $\times 200$ 406 were captured by NanoZoomer-SQ (Catalog No. C13140-01, Hamamatsu, Shizuoka, 407 Japan) and NDP.view2 software (Hamamatsu). Image-Pro Plus (Media Cybernetics) 408 was used for measurement of the vascular area and the villous area. The mean of the 409 percentage of vascular area in villous area in 5 images was defined as the vascular 410 area density.

411 **RNA extraction and qRT-PCR**

RNA was extracted using TRIzol (Catalog No. 15596018, Thermo Fisher Scientific), and then reverse-transcribed into cDNA. qRT-PCR was conducted with the SYBRTM Green Master Mix reagent (Catalog No. A25742, Thermo Fisher Scientific). Internal reference gene was *glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*). All experiments were replicated three times independently. Sangon Biotech Corporation (Shanghai, China) supplied the primers (Table S6).

418 Cell culture

Immortalized HUVECs were a generous gift from Peking University Third Hospital
Medical Research Center. HUVECs were cultured in DMEM/F-12 medium (Catalog
No. C11330500BT, Thermo Fisher Scientific) containing 1% penicillin/streptomycin
(Catalog No. V900929, Sigma-Aldrich, St. Louis, MO) as well as 10% fetal bovine
serum (FBS) (Catalog No. 10099141, Thermo Fisher Scientific) at 37°C with 5% CO₂.
HUVECs were authenticated with short tandem repeat analysis.

425 Cell transfection

426 Transient transfection of HUVECs with siRNA was performed at 70% confluence in 427 six-well plates using Lipofectamine 3000 (Catalog No. L3000015, Thermo Fisher 428 Scientific). MTDH siRNA sequences were as follows: sense, (5'-3')429 GGAACCAAUUCCUGAUGAUTT: antisense (5'-3')430 AUCAUCAGGAAUUGGUUCCTT. The siRNA was synthesized by GenePharma 431 (Shanghai, China).

432 Western blotting

433 Proteins (20 mg for each sample) were electrophoresed on 8% SDS-PAGE gels and 434 then transferred to polyvinylidene fluoride membranes (Catalog No. IPVH00010, 435 Millipore Bedford, MA). The membranes were blocked in 5% nonfat dry milk 436 followed by incubating with anti-MTDH antibody (1:10,000; Catalog No. ab124789, 437 Abcam) and anti-GAPDH antibody (1:5000; Catalog No. ab8245, Abcam) overnight at 4°C. After incubating with secondary antibodies, the bands were revealed with an 438 439 enhanced ECL Kit (Catalog No. BF06053-500, Biodragon, Beijing, China) and 440 analyzed by ImageJ (National Institutes of Health, NIH) using GAPDH as the loading 441 control.

442 **Real-time cell proliferation and migration assays**

443 The RTCA analyzer (ACEA Biosciences, San Diego, CA) was used to examine cell 444 proliferation and migration abilities. The cell proliferation assay was carried out on the E-plate with each well consisting of $5 \square \times \square 10^3$ cells treated with si-*MTDH* or 445 si-NC. The impedance of each well, expressed as the cell index (CI), was 446 447 automatically measured every 30 min for 60 h. The migration assay was performed in a CIM-16 plate. A total of $2 \square \times \square 10^4$ transfected cells were seeded into the upper 448 449 chamber with serum-free medium, while it was complete medium in the lower 450 chamber. Scans were run with sweeps every 15 min for 60 h. The impendence of each 451 well was also represented by the CI.

452 Wound healing assay

In 6-well plates, 5×10^5 HUVECs transfected with either si-*MTDH* or si-NC were seeded per well. When cells reached confluence, scratches were made with 200-µl pipette tips. Afterwards, serum-free medium was used for cell culture, and images were captured every 12 h for a total of 24 h. The NIH ImageJ software was applied to analyze the cell migration distance.

458 **Tube formation assay**

In 96-well plates, 60 μ l of Matrigel (Catalog No. 356234, BD Biosciences, Bedford, MA) was placed in each well, which was then solidified at 37°C for 30 min. Transfected HUVECs (2 × 10⁴/well) were seeded into Matrigel-coated wells and cultured for 8 h. After that, the medium was discarded, and the cells were labeled with

2 μM calcein AM fluorescent dye (Catalog No. ab141420, Abcam) at 37°C for 20 min.
The LeicaDMI4000B inverted microscope was used to observe the capillary-like
structures, and images were taken using a Leica DFC345FX camera. The number and
area of the formed tubes, the number of junctions, as well as the total branching
length were quantified using ImageJ software (NIH). Experiments were performed 3
times independently.

469 **Spheroid sprouting assay**

470 As previously described, we performed the 3D sprouting assay [54]. HUVECs were 471 harvested after 24 h of transfection with either si-MTDH or si-NC to generate endothelial cell spheroids. Briefly, HUVECs $(1 \times 10^3/\text{well})$ were added into 472 473 nonadherent round-bottom 96-well plates, and the cells spontaneously formed a single 474 EC spheroid in each well within 24 h. The spheroids were then embedded in collagen 475 gel and cultured for 48 h. A LeicaDMI4000B inverted microscope was used to 476 observe the spheroids after labeling with calcein AM. ImageJ software (NIH) was 477 used to measure all sprouts originating from each spheroid. The cumulative sprout 478 length of 10 spheroids were compared between the 2 groups. The experiments were 479 replicated 3 times independently.

480 **RNA-seq and data analysis**

RNA was isolated and quality controlled. The cDNA libraries of transfected HUVECs were constructed and purified, followed by sequencing on Illumina NovaSeq platform. Clean reads were achieved by processing raw data with in-house Perl scripts. HISAT2 was used for reads alignment and featureCounts for counting reads. DESeq2 was applied for differentially expressed genes identification (adjusted P < 0.05). DAVID v6.8 was used for gene ontology (GO) analysis. GeneMANIA was carried out to construct protein-protein interaction network.

488 Statistical analysis

Proliferation and migration curves were estimated by two-way ANOVA using SPSS software version 25.0. Paired *t*-test was applied to compare the differences between IUGR twins and the normal cotwins. All other data comparisons were conducted with Student's *t*-test. P < 0.05 was considered statistically significant.

493

494 **Ethical statement**

495 Ethical approval of our study was achieved from the Ethics Committee of the Peking

- 496 University Third Hospital (IRB00006761-2016145). Prior to placental samples
- 497 collection, written informed consent was obtained from participants.

498

499 Data availability

- 500 The placental proteomic data of sIUGR twins have been uploaded to the iProX
- database (https://www.iprox.org/) [55], and are accessible with the dataset identifier
- 502 IPX0004712000. The RNA-seq data of HUVECs have been submitted to the Genome
- 503 Sequence Archive (GSA: HRA002656) at <u>https://ngdc.cncb.ac.cn/gsa-human/</u> [56].

504

505 **Competing interests**

506 All authors declare no competing interests.

507

508 Acknowledgments

- 509 Our investigation was supported by the National Natural Science Foundation of China
- 510 (Grant Nos. 81971399 and 82171661).

511

512 **References**

- [1] Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR):
 epidemiology and etiology. Pediatr Endocrinol Rev 2009;6:332–6.
- [2] Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and
 mortality among very-low-birth-weight neonates with intrauterine growth
 restriction. Am J Obstet Gynecol 2000;182:198–206.
- [3] Barker DJ. The fetal and infant origins of adult disease. BMJ 1990;301:1111.
- [4] Regnault TR, Galan HL, Parker TA, Anthony RV. Placental development in
 normal and compromised pregnancies-- a review. Placenta. 2002;23:S119–29.

- [5] Chaddha V, Viero S, Huppertz B, Kingdom J. Developmental biology of the
 placenta and the origins of placental insufficiency. Semin Fetal Neonatal Med
 2004;9:357–69.
- [6] Gagnon R. Placental insufficiency and its consequences. Eur J Obstet Gynecol
 Reprod Biol 2003;110:S99–107.
- [7] Neerhof MG, Thaete LG. The fetal response to chronic placental insufficiency.
 Semin Perinatol 2008;32:201–5.
- [8] Bennasar M, Eixarch E, Martinez JM, Gratacós E. Selective intrauterine growth
 restriction in monochorionic diamniotic twin pregnancies. Semin Fetal Neonatal
 Med 2017;22:376–82.
- [9] Lopriore E, Pasman SA, Klumper FJ, Middeldorp JM, Walther FJ, Oepkes D.
 Placental characteristics in growth-discordant monochorionic twins: a matched case-control study. Placenta 2012;33:171–4.
- [10] Kalafat E, Thilaganathan B, Papageorghiou A, Bhide A, Khalil A. Significance
 of placental cord insertion site in twin pregnancy. Ultrasound Obstet Gynecol
 2018;52:378–84.
- [11] Gou C, Li M, Zhang X, Liu X, Huang X, Zhou Y, et al. Placental characteristics
 in monochorionic twins with selective intrauterine growth restriction assessed by
 gradient angiography and three-dimensional reconstruction. J Matern Fetal
 Neonatal Med 2017;30:2590–5.
- [12] Chu S, Mao Q, Shapiro S, De Paepe ME. Placental endoglin levels in
 diamniotic-monochorionic twin gestations: correlation with clinical and placental
 characteristics. Placenta 2013;34:261–8.
- [13] Schrey S, Kingdom J, Baczyk D, Fitzgerald B, Keating S, Ryan G, et al. *Leptin* is
 differentially expressed and epigenetically regulated across monochorionic twin
 placenta with discordant fetal growth. Mol Hum Reprod 2013;19:764–72.
- [14] Nevo O, Many A, Xu J, Kingdom J, Piccoli E, Zamudio S, et al. Placental
 expression of soluble *fms-like tyrosine kinase 1* is increased in singletons and
 twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab
 2008;93:285–92.
- [15] Zhang GL, He ZM, Shi XM, Gou CY, Gao Y, Fang Q. Discordant *HIF1A* mRNA levels and oxidative stress in placental shares of monochorionic twins
 with selective intra-uterine growth restriction. Placenta 2015;36:297–303.
- [16] Gou C, Liu X, Shi X, Chai H, He ZM, Huang X, et al. Placental expressions of
 CDKN1C and *KCNQ10T1* in monozygotic twins with selective intrauterine
 growth restriction. Twin Res Hum Genet 2017;20:389–94.
- [17] Roifman M, Choufani S, Turinsky AL, Drewlo S, Keating S, Brudno M, et al.
 Genome-wide placental DNA methylation analysis of severely growth-discordant
 monochorionic twins reveals novel epigenetic targets for intrauterine growth
 restriction. Clin Epigenetics 2016;8:70.

- [18] Reynolds LP, Redmer DA. Angiogenesis in the placenta. Biol Reprod
 2001;64:1033–40.
- [19] Antfolk D, Sjoqvist M, Cheng F, Isoniemi K, Duran CL, Rivero-Muller A, et al.
 Selective regulation of Notch ligands during angiogenesis is mediated by
 vimentin. Proc Natl Acad Sci U S A 2017;114:E4574–81.
- [20] Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic
 interaction between embryonic arteries and veins revealed by *ephrin-B2* and its
 receptor *Eph-B4*. Cell 1998;93:741–53.
- [21] Yeh JJ, Ju R, Brdlik CM, Zhang W, Zhang Y, Matyskiela ME, et al. Targeted
 gene disruption of methionine aminopeptidase 2 results in an embryonic
 gastrulation defect and endothelial cell growth arrest. Proc Natl Acad Sci U S A
 2006;103:10379–84.
- [22] Liu Y, Kong X, Li X, Li B, Yang Q. Knockdown of *metadherin* inhibits
 angiogenesis in breast cancer. Int J Oncol 2015;46:2459–66.
- Long M, Dong K, Gao P, Wang X, Liu L, Yang S, et al. Overexpression of
 astrocyte-elevated gene-1 is associated with cervical carcinoma progression and
 angiogenesis. Oncol Rep 2013;30:1414–22.
- [24] Whitehead CL, Walker SP, Ye L, Mendis S, Kaitu'u-Lino TJ, Lappas M, et al.
 Placental specific mRNA in the maternal circulation are globally dysregulated in
 pregnancies complicated by fetal growth restriction. J Clin Endocrinol Metab
 2013;98:E429–36.
- [25] McMinn J, Wei M, Schupf N, Cusmai J, Johnson EB, Smith AC, et al.
 Unbalanced placental expression of imprinted genes in human intrauterine
 growth restriction. Placenta 2006;27:540–9.
- 585 [26] Sferruzzi-Perri AN, Macpherson AM, Roberts CT, Robertson SA. *Csf2* null
 586 mutation alters placental gene expression and trophoblast glycogen cell and giant
 587 cell abundance in *mice*. Biol Reprod 2009;81:207–21.
- [27] Robertson SA, Roberts CT, Farr KL, Dunn AR, Seamark RF. Fertility
 impairment in granulocyte-macrophage colony-stimulating factor-deficient *mice*.
 Biol Reprod 1999;60:251–61.
- [28] Lambertini L, Li Q, Ma Y, Zhang W, Hao K, Marsit C, et al. Placental imprinted
 gene expression mediates the effects of maternal psychosocial stress during
 pregnancy on fetal growth. J Dev Orig Health Dis 2019;10:196–205.
- [29] Chen X, Bai G, Scholl TO. Spontaneous preterm delivery, particularly with
 reduced fetal growth, is associated with DNA hypomethylation of tumor related
 genes. J Pregnancy Child Health 2016;3:215.
- [30] Matsuda M, Tsutsumi K, Kanematsu T, Fukami K, Terada Y, Takenawa T, et al.
 Involvement of phospholipase C-related inactive protein in the mouse
 reproductive system through the regulation of gonadotropin levels. Biol Reprod
 2009;81:681–9.

- [31] Audette MC, Kingdom JC. Screening for fetal growth restriction and placental
 insufficiency. Semin Fetal Neonatal Med 2018;23:119–25.
- [32] Li W, Chung CYL, Wang CC, Chan TF, Leung MBW, Chan OK, et al.
 Monochorionic twins with selective fetal growth restriction: insight from
 placental whole-transcriptome analysis. Am J Obstet Gynecol
 2020;223:749.e1–16.
- [33] Li X, Wang W, Chen J. Recent progress in mass spectrometry proteomics for
 biomedical research. Sci China Life Sci 2017;60:1093–113.
- [34] Maltepe E, Fisher SJ. Placenta: the forgotten organ. Annu Rev Cell Dev Biol
 2015;31:523–52.
- [35] Herrera E, Ortega-Senovilla H. Lipid metabolism during pregnancy and its
 implications for fetal growth. Curr Pharm Biotechnol 2014;15:24–31.
- [36] Chabrun F, Huetz N, Dieu X, Rousseau G, Bouzille G, Chao de la Barca JM, et
 al. Data-mining approach on transcriptomics and methylomics placental analysis
 highlights genes in fetal growth restriction. Front Genet 2019;10:1292.
- [37] Paules C, Youssef L, Miranda J, Crovetto F, Estanyol JM, Fernandez G, et al.
 Maternal proteomic profiling reveals alterations in lipid metabolism in late-onset
 fetal growth restriction. Sci Rep 2020;10:21033.
- [38] Zur RL, Kingdom JC, Parks WT, Hobson SR. The placental basis of fetal growth
 restriction. Obstet Gynecol Clin North Am 2020;47:81–98.
- [39] Chassen S, Jansson T. Complex, coordinated and highly regulated changes in
 placental signaling and nutrient transport capacity in IUGR. Biochim Biophys
 Acta Mol Basis Dis 2020;1866:165373.
- [40] Huppertz B, Peeters LL. Vascular biology in implantation and placentation.
 Angiogenesis 2005;8:157–67.
- [41] Mayhew TM, Charnock-Jones DS, Kaufmann P. Aspects of human fetoplacental
 vasculogenesis and angiogenesis. III. Changes in complicated pregnancies.
 Placenta 2004;25:127–39.
- [42] Chen CP, Bajoria R, Aplin JD. Decreased vascularization and cell proliferation
 in placentas of intrauterine growth-restricted fetuses with abnormal umbilical
 artery flow velocity waveforms. Am J Obstet Gynecol 2002;187:764–9.
- [43] Manna D, Sarkar D. Multifunctional role of *astrocyte elevated gene-1* (*AEG-1*)
 in cancer: focus on drug resistance. Cancers (Basel) 2021;13.
- [44] Dhiman G, Srivastava N, Goyal M, Rakha E, Lothion-Roy J, Mongan NP, et al.
 Metadherin: a therapeutic target in multiple cancers. Front Oncol 2019;9:349.
- [45] Melamed N, Baschat A, Yinon Y, Athanasiadis A, Mecacci F, Figueras F, et al.
 FIGO (international federation of gynecology and obstetrics) initiative on fetal
 growth: best practice advice for screening, diagnosis, and management of fetal
 growth restriction. Int J Gynaecol Obstet 2021;152:3–57.

- 640 [46] Smith GCS. Universal screening for foetal growth restriction. Best Pract Res
 641 Clin Obstet Gynaecol 2018;49:16–28.
- [47] Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal
 weight with the use of head, body, and femur measurements a prospective-study.
 Am J Obstet Gynecol 1985;151:333–7.
- [48] Wyatt SM, Kraus FT, Roh CR, Elchalal U, Nelson DM, Sadovsky Y. The
 correlation between sampling site and gene expression in the term human
 placenta. Placenta 2005;26:372–9.
- [49] Sood R, Zehnder JL, Druzin ML, Brown PO. Gene expression patterns in human
 placenta. Proc Natl Acad Sci U S A 2006;103:5478–83.
- [50] Cox J, Mann M. MaxQuant enables high peptide identification rates,
 individualized p.p.b.-range mass accuracies and proteome-wide protein
 quantification. Nat Biotechnol 2008;26:1367–72.
- [51] Magrane M. UniProt knowledgebase: a hub of integrated protein data. Database(Oxford) 2011;2011:bar009.
- [52] Zhou T, Li C, Zhao W, Wang X, Wang F, Sha J. MaxReport: An enhanced
 proteomic result reporting tool for MaxQuant. PLoS One 2016;11:e0152067.
- [53] Deutsch EW, Mendoza L, Shteynberg D, Farrah T, Lam H, Tasman N, et al. A
 guided tour of the Trans-Proteomic Pipeline. Proteomics 2010;10:1150–9.
- [54] Cattaneo MG, Lucci G, Vicentini LM. Oxytocin stimulates *in vitro* angiogenesis
 via a Pyk-2/Src-dependent mechanism. Exp Cell Res 2009;315:3210–9.
- [55] Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome
 resource. Nucleic Acids Res 2019;47:D1211–7.
- [56] Chen T, Chen X, Zhang S, Zhu J, Tang B, Wang A, et al. The genome sequence
 archive family: toward explosive data growth and diverse data types. Genomics
 Proteomics Bioinformatics 2021;19:578–83.

666

667 Figure Legends

Figure 1 Identification and biofunction analysis of DEPs in IUGR twin placentas

670 **A.** Proteomic workflow for placental tissues from normal cotwins and IUGR twins. 671 Twelve samples from 6 sIUGR pregnancies were enrolled in this study and labeled 672 with two sets of six-plex TMT reagents. **B.** Histogram plot showing the \log_2 FC 673 distribution of all identified proteins. C. Volcano plot of DEPs between IUGR twin 674 placentas and normal cotwin placentas. DEPs were selected with P < 0.05 and |FC| >675 1.3. Red spots indicate the downregulated DEPs, blue spots represent the upregulated 676 DEPs, and gray spots indicate proteins without significantly different expression. D. 677 Heatmap of the DEPs identified in IUGR twin placentas. Proteins are represented by 678 rows, and samples by columns. E. Functional analysis of the DEPs in IUGR twin 679 placentas using IPA software. DEPs, differentially expressed proteins; IUGR, 680 intrauterine growth restriction; sIUGR, selective IUGR; RPLC, reverse-phase liquid 681 chromatography; FC, fold change; LC-MS/MS, liquid chromatography tandem mass spectrometry; N, normal cotwin; I, IUGR twin; TMT, tandem mass tag; IPA, 682 683 ingenuity pathway analysis.

684

685 Figure 2 Impairment of angiogenesis in IUGR twin placentas

686 **A.** IPA identified the "angiogenesis" annotation to be affected in IUGR twin placentas. 687 B. Immunostaining of CD34 in human placentas from IUGR twins and normal 688 cotwins. CD34 is limited to endothelial cells. Scale bar, 50 µm. C. Placental MVD in 689 IUGR twins and normal cotwins. D. Placental vascular area density in IUGR twins 690 and normal cotwins. E. Immunohistochemical images of EFNB2, VIM, and METAP2 691 in placental shares from IUGR twins and normal cotwins. Scale bar, 100 µm. F-H. 692 EFNB2, VIM, and METAP2 immunostaining intensity per tissue area is represented 693 by the fold-decrease relative to the normal control mean. I-K, qRT-PCR analysis 694 showed that the *EFNB2*, *VIM*, and *METAP2* transcriptional levels were significantly 695 lower in placentas of IUGR twins compared with normal cotwins. All data are shown

- 696 as mean \pm SD with 6 samples per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- 697 MVD, microvessel density; NC, negative control; SD, standard deviation.
- 698

699 Figure 3 MTDH expression is downregulated in IUGR twin placentas, and

700 *MTDH* knockdown impairs HUVECs proliferation and migration

- 701 **A.** *MTDH* mRNA levels in IUGR twin placentas (n = 6) and normal cotwin placentas 702 (n = 6) by qRT-PCR analysis. **B.** MTDH expression in placental shares of IUGR twins 703 and normal cotwins by immunohistochemistry. Scale bar, 100 µm. C. MTDH 704 immunostaining intensity in IUGR twin and normal cotwin placentas (n = 6 in each 705 group). **D-F.** After transfection for 48 h, the interference efficiency of siRNA 706 targeting MTDH in HUVECs was evaluated by qRT-PCR (**D**) and western blotting 707 (E). The relative intensity of MTDH levels was evaluated by ImageJ from three 708 independent experiments (F). G. Proliferation curves showed that MTDH knockdown 709 greatly inhibited HUVECs proliferation. Two-way ANOVA was used for data analysis. 710 **H.** Migration curves revealed that *MTDH* knockdown greatly inhibited HUVECs 711 migration. Two-way ANOVA was used for data analysis. I-J. Knockdown of MTDH 712 in HUVECs decreased the rate of wound closure. Scale bar, 100 µm. All experiments had 3 replicates with results shown as mean \pm SD. *, P < 0.05; **, P < 0.01; ***, P <713 714 0.001. ANOVA, analysis of variance.
- 715

Figure 4 *MTDH* knockdown inhibits HUVECs tube formation and spheroid sprouting

718 **A.** HUVECs were harvested 48 h after transfection with si-NC or si-*MTDH* and then 719 plated in Matrigel-coated wells. After 8 h, HUVEC tube formation was observed 720 under a LeicaDMI4000B microscope and photographed. Scale bar, 100 µm. B-E. 721 Quantification of the number of tubes (**B**), total tube length (**C**), total tube area (**D**), 722 and number of branching points (E) in the si-*MTDH* group and the si-NC group using 723 ImageJ software. The results were from three independent assays. F. si-NC or 724 si-MTDH transfected HUVECs spheroids were photographed 48 h later after 725 embedding in collagen gels. Scale bar, 100 μ m. G. ImageJ software was used to

quantify the cumulative sprout length in the si-*MTDH* group and the si-NC group. All data are expressed as mean \pm SD from 3 experiments. **, P < 0.01; ***, P < 0.001.

728

729 Figure 5 RNA-seq analysis of HUVECs following *MTDH* interference

A. Correlation coefficient analysis based on RNA-seq data for each sample pair. Three replicates per condition. **B.** Heatmap of the top 50 differentially expressed protein-coding genes between si-*MTDH* group and si-NC group. Genes are represented by rows, and samples by columns. **C.** Bubble plot depicting biological process enrichment for 50 candidates by gene ontology. **D.** Interaction network of the 50 candidate genes. The network was constructed by GeneMANIA and visualized using Cytoscape 3.7.2.

737

738

739


740 Supplementary material

741 Figure S1 Clinical characteristics and placental histopathology of sIUGR twins


742 A–B. Representative images of ultrasound biometric measurements of the normal 743 cotwin (A) and the IUGR twin (B) from a sIUGR pregnancy, including BPD, HC, AC, 744 and FL. C. Ultrasound estimated fetal weight of the normal cotwins and the IUGR 745 twins from six pairs of sIUGR pregnancies throughout gestation were plotted on the 746 fetal growth curve. **D.** Birth weight of the normal cotwins and the IUGR twins (n = 6)747 in each group). E. Normal placental parenchyma from the normal cotwin. Scale bar, 748 $100 \,\mu\text{m}$. F. Distal villous hypoplasia in the IUGR twin placenta. Scale bar, $100 \,\mu\text{m}$. G. 749 Increased fibrin deposition (arrow) in the IUGR twin placenta. Scale bar, 100 µm. H. 750 Increased syncytial knots (arrow) in the IUGR twin placenta. Scale bar, 100 μ m. I. A 751 representative image of sIUGR twin placenta after dye injection. Placental sharing 752was indicated by the white dotted line. Velamentous cord insertion was observed in the IUGR twin. ***, P < 0.001. BPD, biparietal diameter; HC, head circumference; 753 754 AC, abdominal circumference; FL, femur length.

~	_	_
	n	n


756	Figure S2	Bioinformatic analysis of the DEPs in IUGR twin placentas by IPA	
757	software		
758	A. DEPs s	ignificantly enriched in the "molecular and cellular function" category. B.	
759	DEPs significantly enriched in the "disease and disorder" category. C. Canonical		
760	pathway analysis of the DEPs.		
761			
762	Table S1	Clinical features of 6 sIUGR twins	
763			
764	Table S2	Detailed information on 5481 nonredundant proteins identified in	
765	sIUGR tw	in placentas	
766			
767	Table S3	Detailed information on 233 DEPs in IUGR twin placentas	
768			
769	Table S4	Detailed information on the biofunction analysis by IPA	
770			
771	Table S5	The top 50 differentially expressed protein-coding genes between the	
772	si-MTDH group and the si-NC group		
773			
774	Table S6	Primers used for qRT-PCR	





55 (92) 38 (91) 28 (91) 11 (91) 11 (91) 66 (92) 31 (91) 31 (91) 55 (92) 11 (91)





Physiological system development and function




















Α

3.


0.961


0.962

0.961

0.982

0.983





Target gene Genes related to fetal growth Other genes